Lineage Cell Therapeutics Inc

ASE:LCTX   3:59:51 PM EDT
2.55
-0.08 (-3.04%)
Products, Regulatory

Lineage Cell Therapeutics Says Opc1 Cell Therapy For The Treatment Of Spinal Cord Injury To Return To Clinical Testing

Published: 06/22/2021 10:57 GMT
Lineage Cell Therapeutics Inc (LCTX) - Lineage’s Opc1 Cell Therapy for the Treatment of Spinal Cord Injury to Return to Clinical Testing.
Lineage Cell Therapeutics Inc - Safety Study Eligibility is Expected to Include Patients With Chronic Injury.
Lineage Cell Therapeutics Inc - Late-stage Clinical Study Continues to Be Planned for 2022.
Lineage Cell Therapeutics Inc - Rmat Interaction With FDA Held to Propose Clinical Testing of a Novel Delivery Device for Opc1.
Lineage Cell Therapeutics Inc - Intends to Submit an Amendment to Its Ind Application for Opc1 to Support a Phase 1 Clinical Study.